|
Via clinical study, a healthcare professional reported injecting a patient in the midface, temples, and chin with 5.1 ml of juvéderm® voluma¿ xc, in the lips and perioral with 1.15 ml of juvéderm® volbella¿ xc, and in the cheek with 3 ml of skinvive¿ by juvéderm®.A month later, the patient was injected in the midface, chin, and temples with 5.1 ml of juvéderm® voluma¿ xc, in the lips with 0.2 ml of juvéderm® volbella¿ xc, in the jawline with 0.7 ml of juvéderm® volux¿ xc, in the nasolabial folds with 1 ml of juvéderm® vollure¿ xc, and in the cheek with 1 ml of skinvive¿ by juvéderm®.A month later, the patient was injected in the nasolabial folds with 0.6 ml of juvéderm® vollure¿ xc and in the jawline with 0.3 ml of juvéderm® volux¿ xc.Two months later, the patient experienced non-device related ¿left sided squamous cell carcinoma of the tongue.¿ two days later, the patient experienced non-device related ¿urinary tract infection¿ and ¿dehydration.¿ the ¿dehydration¿ resolved that day, and the ¿urinary tract infection¿ resolved a week later.The ¿left sided squamous cell carcinoma of the tongue¿ was ongoing.
|
|
Clarification to h.6.Type of investigation code: the filler was injected into the patient and is not accessible for return.The syringe was not returned for evaluation.Abbvie is unable to confirm with the healthcare professional; therefore, additional event, product, or patient details are not attainable.The event is a physiological complication and analysis of the device generally does not assist allergan in determining a probable cause for this event.The event of "left sided squamous cell carcinoma of the tongue", deemed not device related, is considered an unexpected adverse drug experience.
|